Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomilnacipran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1R,2S-Milnacipran SCHEMBL30083111 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL12027608 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1707471 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL5504533 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL8099 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL114034 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL1156056 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL4434769 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL16241424 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1289763 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| EP-4713433-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | Children's Hospital Medical Center (US) | 2026-03-25 | — | — | EP | claimed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-01-29 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-20130210919-A1 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE | FOREST LAB HOLDINGS LTD (US) | 2013-08-15 | — | — | US | claimed |
| EP-1908461-B9 | Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine | PF MEDICAMENT (FR) | 2011-08-31 | — | — | EP | claimed |
| US-20110112197-A1 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2011-05-12 | — | — | US | claimed |
| EP-2305225-A1 | Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine | PIERRE FABRE MEDICAMENT (FR) | 2011-04-06 | — | — | EP | claimed |
| EP-1908461-B1 | Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine | PF MEDICAMENT (FR) | 2011-03-16 | — | — | EP | claimed |
| EP-1601349-B1 | USE OF THE ENANTIOMER (1S, 2R) OF MILNACIPRAN FOR THE PREPARATION OF A MEDICAMENT | PF MEDICAMENT (FR) | 2008-07-23 | — | — | EP | claimed |
| EP-1908461-A1 | Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine | PIERRE FABRE MEDICAMENT (FR) | 2008-04-09 | — | — | EP | claimed |
| US-20060014837-A1 | Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2006-01-19 | — | — | US | claimed |
| US-20040259953-A1 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2004-12-23 | — | — | US | claimed |
| US-20040162334-A1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2004-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544385-B2 | Combination drug therapies for CNS disorders | SLC6A3, SLC6A2, SLC18A2 | SLC6A2 2/4885SLC6A4 4/4885SLC6A3 1/4885 |
| US-20110112197-A1 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE | UACA, CPS1, CYCS | SLC6A2 4433/4885SLC6A4 3972/4885SLC6A3 3927/4885 |
| US-20060014837-A1 | Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug | SLC6A2, ADRA1D, HTR3A | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 20/4885 |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | SLC6A2 782/4885SLC6A4 153/4885SLC6A3 384/4885 |
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | NTSR1, NTSR2, GPR39 | SLC6A2 6/4885SLC6A4 13/4885SLC6A3 96/4885 |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | OPRD1, CRH, HTR2C | SLC6A2 10/4885SLC6A4 23/4885SLC6A3 6/4885 |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | CAMK1, CAMK2B, CAMK4 | SLC6A2 465/4885SLC6A4 806/4885SLC6A3 1206/4885 |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | CHRNA2, CHRNA3, ADRA2B | SLC6A2 4/4885SLC6A4 85/4885SLC6A3 69/4885 |
| US-20130210919-A1 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE | UACA, CPS1, CYCS | SLC6A2 4433/4885SLC6A4 3972/4885SLC6A3 3927/4885 |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | SLC6A4, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 1/4885SLC6A3 3/4885 |
| US-20040259953-A1 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug | SLC6A2, ADRA1D, HTR3A | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 20/4885 |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | HTR2C, SLC6A3, HTR3C | SLC6A2 10/4885SLC6A4 22/4885SLC6A3 2/4885 |
| US-20040162334-A1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | SLC6A4, SLC6A2, HTR6 | SLC6A2 2/4885SLC6A4 1/4885SLC6A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.